Portola Pharmaceuticals Inc  

(Public, NASDAQ:PTLA)   Watch this stock  
Find more results forPTLA
+3.88 (8.81%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.80 - 47.97
52 week 24.75 - 57.96
Open 43.01
Vol / Avg. 0.00/513,371.00
Mkt cap 2,517.79M
P/E     -
Div/yield     -
EPS -3.74
Shares 52.56M
Beta     -
Inst. own 97%
Nov 2, 2015
Q3 2015 Portola Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 17, 2015
Portola Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Aug 4, 2015
Q2 2015 Portola Pharmaceuticals Inc Earnings Call - Webcast
Aug 4, 2015
Q2 2015 Portola Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -2445.66% -1424.67%
Operating margin -2466.54% -1429.26%
EBITD margin - -1413.24%
Return on average assets -50.40% -36.95%
Return on average equity -59.45% -42.58%
Employees 99 -
CDP Score - -


270 East Grand Avenue, Suite 22
United States - Map
+1-650-2446864 (Phone)
+1-650-2467376 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.

Officers and directors

Charles J. Homcy M.D. Co-Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Hollings C. Renton III Independent Co-Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
William Lis Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mardi C. Dier Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John T. Curnutte M.D. Ph.D. Executive Vice President - Research & Development
Age: 63
Bio & Compensation  - Reuters
Tao Fu Executive Vice President, Chief Commercial and Business officer
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 57
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
John H. Johnson Director
Age: 57
Bio & Compensation  - Reuters
David C. Stump M.D. Director
Age: 65
Bio & Compensation  - Reuters